| Target and Pathway |
Top |
| Target(s) |
Matrix metalloproteinase-13 (MMP-13) |
Target Info
|
Inhibitor |
[1] |
| Matrix metalloproteinase-2 (MMP-2) |
Target Info
|
Inhibitor |
[1] |
| Target's Patent Info |
Matrix metalloproteinase-13 (MMP-13) |
Target's Patent Info
|
[1] |
| Matrix metalloproteinase-2 (MMP-2) |
Target's Patent Info
|
[1] |
|
KEGG Pathway
|
Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Bladder cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling Pathway
|
|
Panther Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
Pathway Interaction Database
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Endochondral Ossification
|
|
Activation of Matrix Metalloproteinases
|
|
Oncostatin M Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Matrix Metalloproteinases
|
